查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726215

前列腺癌生物標記市場規模、佔有率、趨勢分析報告：按類型、應用、最終用途、地區和細分市場預測，2025 年至 2030 年

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report By Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

前列腺癌生物標記市場的成長和趨勢

根據 Grand View Research, Inc. 的新報告，全球前列腺癌生物標記市場規模預計到 2030 年將達到 98 億美元，2025-2030 年期間的複合年成長率為 13.1%。

由於對精準診斷的需求不斷增加以及 PSA 測試等傳統篩檢方法的局限性，市場正在快速發展。儘管PSA檢測被廣泛使用，但其特異性較低，並且經常導致過度診斷和過度治療。因此，人們明顯轉向使用分子和基因生物標記來提高診斷準確性並指南臨床決策。 PCA3（前列腺癌抗原 3）、4Kscore 和 ConfirmMDx 等新興生物標記在風險分層和切片檢查決策支持方面表現出色。這些測試擴大被納入臨床實踐中，以減少不必要的切片檢查並改善患者的治療效果。

一個主要的市場驅動力是對個人化醫療的日益關注。 Decipher GPS 和 Oncotype DX GPS 等基因組分類方法可以幫助前列腺腫瘤進行分級並為治療計劃提供資訊。液態切片技術也因其非侵入性而受到關注，基於尿液的測試（例如 SelectMDx 和 ExoDx）為 PSA 升高的患者提供了可進行臨床操作的見解。當傳統切片檢查存在風險或結果不確定時，這些創新尤其重要。

次世代定序儀(NGS) 和轉錄組學的技術進步正在進一步加速生物標記的發現。例如，研究已將TMPRSS2-ERG等基因融合以及BRCA1/2和ATM的突變確定為預後和治療指南的重要標記。這些生物標記在選擇接受 PARP 抑制劑等標靶治療的患者時的應用日益廣泛，反映了伴隨診斷在治療生態系中日益成長的重要性。此外，分析與腫瘤進展相關的小分子代謝變化的代謝組學生物標記正在成為早期檢測和監測的有希望的工具。

然而，市場仍面臨一些挑戰。生物標記檢測的標準化仍然有限，臨床醫生對於在哪個臨床階段應該採用哪些檢測尚未達成共識。報銷問題和成本問題可能會阻礙先進生物標記測試的常規使用，尤其是在醫療預算受限的地區。此外，生物標記的核准流程通常很長，可能會延遲商業化。即使市場上出現了較新的測試，廣泛的臨床應用也需要大量的檢驗研究和與現有臨床工作流程的整合。

儘管存在這些障礙，前列腺癌生物標記行業仍存在顯著的成長機會。學術界和工業界之間的合作正在加速，以發現和檢驗新的生物標記組。隨著人們越來越意識到 PSA 檢測的局限性以及對價值導向醫學的重視，人們越來越傾向於採用更具資訊量、侵入性更小的診斷方法。在此背景下，用於監測晚期前列腺癌抗治療性的AR-V7 等生物標記為生物標記指導治療選擇提供了潛力。

隨著這一領域的不斷發展，前列腺癌診斷正在朝著更全面和個人化的模式發展，其中分子見解不僅可以指導早期檢測，還可以指導治療方法決策和長期管理策略。

市場的主要參與企業包括 Exact Sciences、Myriad Genetics、Bio-Techne、Olympus Corporation 和 OPKO Health。這些公司正在採取各種策略性舉措，包括產品發布和核准，以服務其全球客戶。例如，2024 年 12 月，Myriad Genetics 的 Prolaris 測試繼續獲得美國國家綜合癌症網路 (NCCN) 的核准，成為前列腺癌預後的高級工具。它繼續被納入 NCCN 指南，其 2A 類證據等級表明其獲得了 NCCN 前列腺專家組的大力支持 (>=85%)。這種分類加強了 Prolaris 的臨床相關性，有助於根據腫瘤侵襲性指導治療決策。

前列腺癌生物標記市場報告重點

  • 根據類型，蛋白質生物標記在 2024 年佔據了最大的收入佔有率，為 57.73%。前列腺癌生物標記市場中的蛋白質生物標記部分受到 PSA 和 PHI 測試的廣泛臨床應用、前列腺癌發病率的上升以及對臨床指南的大力支持的推動。多重檢測和 4Kscore 等風險分層工具的技術進步正在提高診斷的準確性。此外，對非侵入性和經濟高效的就地檢驗方案的需求不斷成長，正在推動這一領域在已開發市場和新興市場的進一步成長。
  • 篩檢和早期檢測將佔據市場主導地位，到 2024 年將佔據 45.14% 的最大佔有率。篩檢和早期檢測市場的發展受到疾病盛行率上升、人口老化和非侵入性檢測的採用的推動。例如，PSA 檢測仍然是全球標準，而前列腺健康指數 (PHI) 和 4Kscore 提高了特異性並減少了不必要的切片檢查。美國預防服務工作組 (USPSTF) 建議 55 至 69 歲的男性進行 PSA 檢測等項目進一步推動了需求。社會意識的增強和診斷服務的改善也支持了這一領域的成長。
  • 醫院和診斷實驗室是前列腺癌生物標記行業的主要推動者，因為它們在患者診斷、切片檢查評估和治療計劃中發揮核心作用。患者數量的增加、先進診斷基礎設施的可用性以及對 PSA、PHI 和 ConfirmMDx 等準確的早期檢測測試的需求正在推動市場成長。此外，將生物標記檢測整合到常規泌尿系統工作流程和醫院癌症篩檢計畫中，將進一步推動已開發地區和新興地區對此檢測的採用和發展。
  • 北美憑藉其先進的診斷能力、精準醫療的早期採用以及支持性的法規結構，在前列腺癌生物標記市場佔據主導地位。基於生物標記的測試，例如 ExoDx Prostate（來自 Bio-Techne 的基於尿液的外泌體 RNA 測試）和 SelectMDx（來自 MDxHealth 的 mRNA 測試）被廣泛用於指導切片檢查決策。此外，美國國家綜合癌症網路 (NCCN) 臨床指南建議使用生物標記。基因組學投資的增加以及學術中心和生物技術公司之間的合作繼續推動全部區域的創新和生物標記的採用。
  • 預計 2025-2030 年預測期內亞太地區成長最快，複合年成長率為 14.4%。這是由於中國、印度和日本等國家對癌症意識的不斷提高、醫療保健基礎設施的改善以及醫療保健支出的增加。擴大 PSA 篩檢、PHI 和 4Kscore 等新檢測的覆蓋範圍正在推動早期檢測。地方政府正在推出全國癌症篩檢舉措，對精準醫療和分子診斷的投資不斷增加，推動生物標記的採用。當地醫院和生物技術公司的合作進一步支持了創新和市場擴張。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 前列腺癌生物標記市場變數、趨勢和範圍

  • 前列腺癌生物標記市場的系統性概述
    • 母市場展望
  • 滲透和成長前景圖
  • 管道分析
    • 篩檢和早期檢測
    • 診斷和風險分層
    • 預後和治療監測
    • 伴隨診斷
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 前列腺癌生物標記：市場分析工具
    • 產業分析—波特五力分析
    • PESTLE分析

4. 前列腺癌生物標記市場：細分分析（按類型），2018-2030

  • 前列腺癌生物標記市場：類型變異分析

5. 前列腺癌生物標記市場：細分分析、應用分析，2018-2030

  • 前列腺癌生物標記市場：應用變異分析

6. 前列腺癌生物標記市場：細分分析、依最終用途，2018-2030 年

  • 前列腺癌生物標記市場：最終用途變異分析

7. 前列腺癌生物標記市場：區域細分分析，2018-2030

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

8.前列腺癌生物標記市場競爭分析

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2022年公司市場佔有率分析
  • 公司簡介
    • EXACT SCIENCES CORPORATION
    • MYRIAD GENETICS, INC.
    • BIO-TECHNE
    • EXODX
    • OPKO HEALTH,INC.
    • MDXHEALTH
    • VERACYTE, INC.
    • BECKMAN COULTER, INC.
    • NUCLEIX
    • DIACARTA
Product Code: GVR-4-68040-547-6

Prostate Cancer Biomarkers Market Growth & Trends:

The global prostate cancer biomarkers market size is expected to reach USD 9.8 billion by 2030, registering a CAGR of 13.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is undergoing rapid evolution driven by the increasing demand for precision diagnostics and the limitations of conventional screening methods like PSA testing. PSA, while widely used, has low specificity, often leading to overdiagnosis and overtreatment. As a result, there is a significant shift towards molecular and genomic biomarkers that can offer improved diagnostic accuracy and guide clinical decisions. Emerging biomarkers such as PCA3 (Prostate Cancer Antigen 3), 4Kscore, and ConfirmMDx have demonstrated superior performance in risk stratification and biopsy decision support. These tests are increasingly being integrated into clinical practice to reduce unnecessary biopsies and improve patient outcomes.

A key market driver is the growing focus on personalized medicine. Genomic classifiers like Decipher and Oncotype DX GPS help determine the aggressiveness of prostate tumors and inform treatment planning, especially in early-stage patients deciding between active surveillance and intervention. Liquid biopsy-based technologies are also gaining attention for their non-invasive nature, with urine-based tests like SelectMDx and ExoDx offering clinically actionable insights for patients with elevated PSA. These innovations are particularly relevant in cases where traditional biopsies carry risks or yield inconclusive results.

Technological advancements in next-generation sequencing (NGS) and transcriptomics are further accelerating biomarker discovery. For example, studies have identified gene fusions such as TMPRSS2-ERG and mutations in BRCA1/2 and ATM as significant markers for prognosis and therapeutic guidance. The increasing use of these biomarkers in selecting patients for targeted therapies like PARP inhibitors reflects the rising importance of companion diagnostics in the treatment ecosystem. Moreover, metabolomic biomarkers, which analyze small-molecule metabolic changes associated with tumor progression, are emerging as promising tools for early detection and monitoring.

However, the market still faces several challenges. Standardization across biomarker assays remains limited, and there is a lack of consensus among clinicians regarding which tests to adopt and at what clinical stages. Reimbursement issues and cost concerns can hinder the routine use of advanced biomarker tests, particularly in regions with constrained healthcare budgets. Furthermore, regulatory pathways for biomarker approval are often lengthy, which can delay commercial availability. Even as newer tests enter the market, widespread clinical adoption requires large-scale validation studies and integration into existing clinical workflows.

Despite these barriers, the prostate cancer biomarker industry presents notable growth opportunities. Collaborations between academia and industry are intensifying, aimed at discovering and validating novel biomarker panels. With increasing awareness of the limitations of PSA and growing emphasis on value-based care, there is strong momentum to shift toward more informative, less invasive diagnostics. In this context, biomarkers like AR-V7, used for monitoring treatment resistance in advanced prostate cancer, illustrate the potential of biomarker-guided therapy selection.

As the field continues to advance, prostate cancer diagnostics are moving toward a more integrated and individualized model, where molecular insights guide not only early detection but also therapeutic decisions and long-term management strategies.

Some of the key players in the market are Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in December 2024, Myriad Genetics' Prolaris test continues to be recognized by the National Comprehensive Cancer Network (NCCN) as an Advanced Tool for prostate cancer prognosis. It remains included in the NCCN guidelines with a Category 2A evidence level, indicating strong support (>=85%) from the NCCN prostate panel. This classification reinforces Prolaris' clinical relevance in helping guide treatment decisions based on tumor aggressiveness.

Prostate Cancer Biomarker Market Report Highlights:

  • Based on type, protein biomarkersaccounted for largest revenue share of 57.73% in 2024. The protein biomarkers segment in the prostate cancer biomarkers market is driven by the widespread clinical use of PSA and PHI tests, rising prostate cancer prevalence, and strong clinical guideline support. Technological advances in multiplex assays and risk stratification tools like the 4Kscore enhance diagnostic accuracy. Additionally, increased demand for non-invasive, cost-effective, and point-of-care testing solutions fuels further growth in this segment across both developed and emerging markets.
  • Based on application screening and early detection dominated the market and accounted for the largest share of 45.14% in 2024.The screening and early detection segment in the market is driven by rising disease prevalence, aging populations, and adoption of non-invasive tests. For example, PSA testing remains a global standard, while PHI (Prostate Health Index) and the 4Kscore offer improved specificity, reducing unnecessary biopsies. Programs like the U.S. Preventive Services Task Force (USPSTF) recommendation for PSA testing in men aged 55-69 further boost demand. Increased public awareness and improved access to diagnostic services also support growth in this segment.
  • Based on end use, hospitals and diagnostic laboratories segment dominated the market and accounted for the largest share of 63.24% in 2024.Hospitals and diagnostic laboratories are key drivers in the prostate cancer biomarker industry due to their central role in patient diagnosis, biopsy evaluation, and treatment planning. Increasing patient volumes, availability of advanced diagnostic infrastructure, and demand for accurate, early-stage detection tests like PSA, PHI, and ConfirmMDx fuel market growth. Additionally, integration of biomarker testing into routine urology workflows and hospital-based cancer screening programs further enhances test adoption and market expansion in both developed and emerging regions.
  • North America dominates the prostate cancer biomarkers market due to advanced diagnostic capabilities, early adoption of precision medicine, and supportive regulatory frameworks. Biomarker-based tests such as ExoDx Prostate (urine-based exosomal RNA test by Bio-Techne) and SelectMDx (mRNA test by MDxHealth) are widely utilized for biopsy decision-making. Additionally, clinical guidelines from the National Comprehensive Cancer Network (NCCN) endorse biomarker usage. Growing investment in genomics and partnerships between academic centers and biotech firms continue to drive innovation and biomarker adoption across the region.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 14.4% over the forecast period from 2025 to 2030, due to increasing cancer awareness, improving healthcare infrastructure, and rising healthcare expenditure in countries like China, India, and Japan. Expanding access to PSA screening and newer tests such as PHI and 4Kscore is driving early detection. Local governments are launching national cancer screening initiatives, and growing investments in precision medicine and molecular diagnostics are boosting biomarker adoption. Collaborations between regional hospitals and biotech firms are further fueling innovation and market expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application and Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Prostate Cancer Biomarkers Market Variables, Trends, and Scope

  • 3.1 Prostate Cancer Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Screening And Early Detection
    • 3.3.2 Diagnosis And Risk Stratification
    • 3.3.3 Prognosis And Treatment Monitoring
    • 3.3.4 Companion Diagnostics
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Rising prevalence of prostate cancer
      • 3.4.1.2 Advancements in Genomic and Proteomic Technologies
      • 3.4.1.3 Supportive Government and Research Initiatives
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 High Cost of Biomarker-Based Tests
      • 3.4.2.2 Uneven Access to Advanced Diagnostic Infrastructure
  • 3.5 Prostate Cancer Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Prostate Cancer Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Prostate Cancer Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genetic Biomarkers
      • 4.1.1.1 Genetic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Protein Biomarkers
      • 4.1.2.1 Protein Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Cell-Based Biomarkers
      • 4.1.3.1 Cell-Based Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Metabolomic Biomarkers
      • 4.1.5.1 Metabolomic Biomarkers Prostate Cancer Biomarkers Market, 2018 - 2030, USD Million

Chapter 5 Prostate Cancer Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Prostate Cancer Biomarkers Market: Application Movement Analysis
    • 5.1.1 Screening And Early Detection
      • 5.1.1.1 Screening And Early Detection Market, 2018 - 2030 (USD Million)
    • 5.1.2 Diagnosis And Risk Stratification
      • 5.1.2.1 Diagnosis And Risk Stratification Market, 2018 - 2030 (USD Million)
    • 5.1.3 Prognosis And Treatment Monitoring
    • 5.3.1 Prognosis And Treatment Monitoring Market, 2018 - 2030 (USD Million)
    • 5.1.4 Companion Diagnostics
      • 5.1.4.1 Companion Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 6 Prostate Cancer Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 Prostate Cancer Biomarkers Market: End Use Movement Analysis
    • 6.1.1 Hospitals And Diagnostic Laboratories
      • 6.1.1.1 Hospitals And Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
    • 6.1.2 Academic And Research Institutes
      • 6.1.2.1 Academic And Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.1.3 Biopharmaceutical Companies
      • 6.1.3.1 Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)

Chapter 7 Prostate Cancer Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Prostate Cancer Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
    • 7.2.4 Mexico
      • 7.2.4.1 Mexico Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.4.2 Key Country Dynamics
      • 7.2.4.3 Regulatory Framework
      • 7.2.4.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Argentina
      • 7.5.3.1 Argentina Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Prostate Cancer Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Prostate Cancer Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New product launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 EXACT SCIENCES CORPORATION
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 MYRIAD GENETICS, INC.
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 BIO-TECHNE
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 EXODX
      • 8.4.4.1 Company overview
      • 8.4.4.2 Product benchmarking
      • 8.4.4.3 Product benchmarking
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 OPKO HEALTH,INC.
      • 8.4.5.1 Company overview
      • 8.4.5.2 Product benchmarking
      • 8.4.5.3 Strategic initiatives
    • 8.4.6 MDXHEALTH
      • 8.4.6.1 Company overview
      • 8.4.6.2 Financial performance
      • 8.4.6.3 Product benchmarking
      • 8.4.6.4 Strategic initiatives
    • 8.4.7 VERACYTE, INC.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
      • 8.4.7.4 Strategic initiatives
    • 8.4.8 BECKMAN COULTER, INC.
      • 8.4.8.1 Company overview
      • 8.4.8.2 Product benchmarking
    • 8.4.9 NUCLEIX
      • 8.4.9.1 Company overview
      • 8.4.9.2 Financial performance
      • 8.4.9.3 Product benchmarking
      • 8.4.9.4 Strategic initiatives
    • 8.4.10 DIACARTA
      • 8.4.10.1 Company overview
      • 8.4.10.2 Product benchmarking
      • 8.4.10.3 Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 8 Canada Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Mexico Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Mexico Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 14 U.K. Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.K. Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 U.K. Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 17 Germany Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 Germany Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 20 France Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 France Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Italy Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 Italy Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Spain Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Spain Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 29 Denmark Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Denmark Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Sweden Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Norway Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Norway Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Japan Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Japan Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 China Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 China Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 India Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 India Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 India Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 South Korea Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 South Korea Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 Australia Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Thailand Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Thailand Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Latin America Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Latin America Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Brazil Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Brazil Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Argentina Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 71 MEA Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 74 South Africa Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 80 UAE Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait Prostate Cancer Biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait Prostate Cancer Biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait Prostate Cancer Biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End Use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2024 (USD Million)
  • Fig. 14 Prostate Cancer Biomarkers market dynamics
  • Fig. 15 Prevalence of Screening and Early Detection by age group, 2024
  • Fig. 16 Prostate Cancer Biomarkers market: PORTER's analysis
  • Fig. 17 Prostate Cancer Biomarkers market: PESTLE analysis
  • Fig. 18 Prostate Cancer Biomarkers market: Type outlook and key takeaways
  • Fig. 19 Prostate Cancer Biomarkers market: Type movement analysis
  • Fig. 20 Genetic Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Protein Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cell-based Biomarkers Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolomic Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Prostate Cancer Biomarkers market: Application outlook and key takeaways
  • Fig. 26 Prostate Cancer Biomarkers market: Application movement analysis
  • Fig. 27 Screening and Early Detection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Diagnosis and Risk Stratification market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Prognosis and Treatment Monitoring market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Companion Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Prostate Cancer Biomarkers market: End Use outlook and key takeaways
  • Fig. 33 Prostate Cancer Biomarkers market: End Use movement analysis
  • Fig. 34 Hospitals and Diagnostic Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Academic and Research Institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Biopharmaceutical Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Prostate Cancer Biomarkers market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Target disease prevalence
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Target disease prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 France Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Target disease prevalence
  • Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Target disease prevalence
  • Fig. 71 Key country dynamics
  • Fig. 72 China Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 India Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Target disease prevalence
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Prostate Cancer Biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Mexico Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Latin America Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 MEA Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Target disease prevalence
  • Fig. 95 Key country dynamics
  • Fig. 96 Saudi Arabia Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target disease prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target disease prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 Kuwait Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target disease prevalence
  • Fig. 104 Key payors in Kuwait
  • Fig. 105 Rest of MEA Prostate Cancer Biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key company categorization
  • Fig. 107 Company market positioning
  • Fig. 108 Company market share analysis, 2022
  • Fig. 109 Strategic framework